title: Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naive patients with genotype 1 hepatitis C virus infection.
authors.affiliation: Department of Medicine, UNSW, Sydney, Australia. m.danta@unsw.edu.au
authors.forename: Mark
authors.initials: M
authors.lastname: Danta